slc39a7 Antibody

What is SLC39A7 and what cellular functions does it regulate?

SLC39A7 (also known as ZIP7) is a zinc transporter protein that plays a critical role in maintaining zinc homeostasis within cells. It functions primarily as a zinc importer, facilitating the movement of Zn²⁺ ions from cellular compartments into the cytoplasm. Research has demonstrated that SLC39A7 regulates several essential cellular processes including:

• Macrophage phagocytosis and activation

• Cell proliferation and differentiation

• Inflammatory cytokine production

• Receptor expression on immune cells

SLC39A7 has been linked to asthma pathophysiology and immune function, particularly in macrophages. Studies show that SLC39A7 deficiency leads to impaired phagocytosis, altered macrophage polarization (skewing toward M2/alternative activation), and reduced production of proinflammatory cytokines like TNF-α and IL-6 . These defects can be rescued through zinc supplementation, indicating SLC39A7's essential role in zinc-dependent cellular processes .

What applications are SLC39A7 antibodies commonly used for?

SLC39A7 antibodies are versatile research tools employed across multiple experimental applications. According to validation data, these antibodies can be reliably used for:

• Western blotting (0.5-1 μg/mL concentration range)

• Immunohistochemistry (2.5 μg/mL)

• Immunocytochemistry/Immunofluorescence (20 μg/mL)

• ELISA (1:100-1:2000 dilution range)

These applications enable researchers to detect SLC39A7 protein expression in various sample types, including cell lysates, tissue sections, and cultured cells . The antibodies have been validated using multiple techniques, including independent antibody validation that confirms specificity across different experimental conditions .

What species reactivity can be expected with available SLC39A7 antibodies?

Available SLC39A7 antibodies demonstrate varied cross-reactivity profiles depending on the specific product. Based on the search results:

• Antibody NBP1-76504 shows reactivity with human, mouse, and rat SLC39A7

• Antibody ABIN2781567 demonstrates broader reactivity including human, dog, pig, cow, horse, rabbit, and sheep

This cross-reactivity is important when designing experiments using animal models. Human SLC39A7 has one isoform (469aa, 50kD), while mouse SLC39A7 has one isoform (476aa, 51kD) and rat SLC39A7 has one isoform (468aa, 50kD) . The high degree of conservation across species facilitates comparative studies between human disease models and animal models.

How should I design experiments to evaluate SLC39A7 function using antibodies?

When designing experiments to investigate SLC39A7 function, a comprehensive approach combining protein detection and functional assays is recommended:

• Baseline expression assessment:

  • Use Western blotting to quantify SLC39A7 expression in your experimental system

  • Apply immunofluorescence to determine subcellular localization

• Functional manipulation:

  • Consider CRISPR-Cas9 gene editing to generate SLC39A7-knockdown cell lines

  • Compare knockdown cells with control cells using functional assays

• Rescue experiments:

  • Include zinc supplementation conditions to determine if phenotypes are zinc-dependent

  • Test different zinc concentrations (5-20 μM range) to establish dose-response relationships

• Downstream effector analysis:

  • Examine expression of relevant receptors (e.g., Clec4e, TLR4)

  • Measure cytokine production (TNF-α, IL-6) using ELISA or flow cytometry

Research has shown that SLC39A7 knockdown significantly decreases phagocytosis efficiency in THP-1 cells, but this defect can be reversed with zinc supplementation . Additionally, SLC39A7 deficiency affects macrophage polarization, reducing M1 marker expression (NOS2) while increasing M2 marker expression (CD206) .

What are the optimal antibody concentrations and conditions for Western blot detection of SLC39A7?

For optimal Western blot detection of SLC39A7, the following protocol parameters are recommended based on validated research methods:

• Sample preparation:

  • Use 15 μg of total protein lysate per lane

  • Include appropriate positive controls (e.g., cell lines known to express SLC39A7)

• Antibody concentrations:

  • Primary antibody: 0.5-1 μg/mL of anti-SLC39A7 antibody

  • Secondary antibody: Anti-rabbit IgG HRP conjugate at 1:10,000 dilution

• Incubation conditions:

  • Primary antibody: 1 hour incubation at room temperature in 5% non-fat dry milk in TBST

  • Secondary antibody: 1 hour at room temperature in the same buffer

• Expected results:

  • Human SLC39A7: ~50 kDa band

  • Mouse SLC39A7: ~51 kDa band

  • Rat SLC39A7: ~50 kDa band

The observed molecular weight may vary from predicted values due to post-translational modifications, cleavages, and relative charges . Validation experiments show clear detection of SLC39A7 in rat brain tissue lysate at both 0.5 μg/mL and 1 μg/mL antibody concentrations .

How can I validate the specificity of an SLC39A7 antibody in my experimental system?

Validating antibody specificity is crucial for obtaining reliable research results. For SLC39A7 antibodies, implement the following validation strategy:

• Multiple antibody comparison:

  • Test at least two independent antibodies targeting different epitopes of SLC39A7

  • Compare banding patterns across different cell lines with varying SLC39A7 expression levels

• Knockdown/knockout validation:

  • Generate SLC39A7 knockdown using CRISPR-Cas9 or siRNA approaches

  • Confirm reduced signal intensity in knockdown samples compared to controls

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing peptide (e.g., peptide corresponding to amino acids near the N-terminus of human SLC39A7)

  • Verify signal reduction or elimination in the presence of competing peptide

• Positive and negative control tissues/cells:

  • Include tissues known to express SLC39A7 (e.g., brain tissue)

  • Test across multiple species if conducting comparative studies

Independent antibody validation data shows consistent detection patterns across different SLC39A7 antibodies, confirming specificity . Western blot analysis comparing SLC39A7 antibodies from different vendors revealed similar banding patterns, further supporting specificity .

How can I investigate the relationship between SLC39A7 and macrophage function?

To investigate SLC39A7's role in macrophage function, a systematic experimental approach is recommended:

• Establish SLC39A7 manipulation model:

  • Generate SLC39A7-knockdown macrophage cell lines (e.g., THP-1) using CRISPR-Cas9

  • Confirm knockdown efficiency by Western blot and qPCR

  • Include non-target transfected control cells as comparison

• Assess phagocytosis capacity:

  • Challenge cells with fluorescently-labeled pathogens (e.g., GFP-expressing BCG)

  • Evaluate phagocytosis using multiple complementary methods:

    • Flow cytometry for quantitative assessment

    • Fluorescence microscopy for visual confirmation

    • Colony-forming unit (CFU) assays to measure viable bacteria

• Examine macrophage polarization:

  • Analyze expression of polarization markers:

    • M1 (classical activation): NOS2

    • M2 (alternative activation): CD206

  • Measure cytokine production (TNF-α, IL-6) by ELISA

• Investigate zinc dependence:

  • Include zinc supplementation conditions (5-20 μM)

  • Determine if zinc can rescue phenotypes in SLC39A7-deficient cells

Research has demonstrated that SLC39A7 expression increases in macrophages during BCG infection . SLC39A7 knockdown results in significantly decreased phagocytosis efficiency, which can be reversed with zinc supplementation . Additionally, SLC39A7-deficient macrophages show reduced expression of Clec4e receptor, which is critical for phagocytosis .

What role does SLC39A7 play in inflammatory responses and how can this be studied?

SLC39A7's role in inflammatory responses can be investigated through the following methodological approach:

• Cytokine profile analysis:

  • Compare cytokine production between SLC39A7-deficient and control cells

  • Measure both pro-inflammatory (TNF-α, IL-6) and anti-inflammatory cytokines

  • Stimulate cells with relevant ligands (e.g., LPS, mycobacterial components)

• Signaling pathway investigation:

  • Examine activation status of NF-κB and MAPK pathways using phospho-specific antibodies

  • Analyze zinc-dependent transcription factors

  • Study temporal dynamics of signaling events after stimulation

• Receptor expression profiling:

  • Quantify expression of pattern recognition receptors:

    • C-type lectin receptors (Clec4e/Mincle)

    • Toll-like receptors (TLR4)

  • Determine if receptor expression changes are zinc-dependent

• Zinc flux measurements:

  • Use zinc-specific fluorescent probes to measure intracellular zinc levels

  • Compare zinc distribution between cellular compartments in normal vs. SLC39A7-deficient cells

Research data indicates that SLC39A7 knockdown results in decreased expression of the C-type lectin receptor Clec4e and increased expression of TLR4 . SLC39A7-deficient cells produce reduced amounts of proinflammatory cytokines TNF-α and IL-6 . Importantly, these inflammatory defects can be reversed by zinc supplementation, suggesting that SLC39A7 regulates inflammatory responses through zinc-dependent mechanisms .

How can SLC39A7 antibodies be used to study its role in disease models?

SLC39A7 antibodies can be valuable tools for investigating this transporter's involvement in disease pathophysiology:

• Clinical sample analysis:

  • Compare SLC39A7 expression in patient vs. healthy control samples

  • Use immunohistochemistry on tissue sections (2.5 μg/mL antibody concentration)

  • Apply Western blotting on protein extracts (0.5-1 μg/mL antibody)

• Animal disease models:

  • Utilize SLC39A7 antibodies validated for your model species (human, mouse, rat)

  • Track SLC39A7 expression changes during disease progression

  • Correlate expression with functional outcomes and disease severity

• Cell-type specific expression:

  • Perform co-staining with cell-type markers and SLC39A7 antibodies

  • Use immunofluorescence (20 μg/mL antibody) for high-resolution localization

  • Identify cell populations with altered SLC39A7 expression in disease states

• Therapeutic intervention assessment:

  • Evaluate how treatments affect SLC39A7 expression

  • Test zinc supplementation strategies to correct SLC39A7-related defects

  • Use antibodies to track changes in protein levels and localization

Research has linked SLC39A7 to asthma pathophysiology, with impaired macrophage phagocytosis, alternative macrophage differentiation, and zinc deficiency all being associated with asthma . SLC39A7-knockdown cells show phenotypes consistent with these disease manifestations, suggesting that SLC39A7 dysfunction may contribute to asthma pathogenesis .

What are common technical challenges when using SLC39A7 antibodies and how can they be addressed?

Researchers working with SLC39A7 antibodies may encounter several technical challenges. These can be addressed through the following strategies:

• Background signal issues:

  • Problem: High background in Western blots or immunostaining

  • Solutions:

    • Optimize blocking conditions (try 5% non-fat dry milk in TBST)

    • Reduce primary antibody concentration (test range from 0.5-1 μg/mL)

    • Increase washing steps (3-5 washes of 5-10 minutes each)

    • Use antibodies that are BSA-free to reduce carrier protein interference

• Multiple banding patterns:

  • Problem: Detection of multiple bands beyond expected molecular weight

  • Solutions:

    • Verify sample preparation (fresh preparation, proper protease inhibitors)

    • Test multiple antibodies targeting different epitopes

    • Include positive control samples with known SLC39A7 expression

    • Consider that post-translational modifications may result in size variations

• Cross-reactivity concerns:

  • Problem: Potential non-specific binding to related zinc transporters

  • Solutions:

    • Select antibodies raised against unique regions of SLC39A7

    • Use knockout/knockdown controls to confirm specificity

    • Perform independent antibody validation comparing multiple antibodies

• Fixation sensitivity:

  • Problem: Certain fixation methods may mask the epitope

  • Solutions:

    • Test multiple fixation protocols (PFA, methanol, acetone)

    • Consider antigen retrieval methods for tissue sections

    • Optimize antibody concentration for each fixation method

Technical validation data shows that antibody NBP1-76504 performs well at 0.5-1 μg/mL for Western blotting and 20 μg/mL for immunofluorescence applications .

How should SLC39A7 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of SLC39A7 antibodies is crucial for maintaining their performance and extending their usable lifespan:

• Storage conditions:

  • Short-term storage (less than 1 month): 4°C

  • Long-term storage: -20°C in small aliquots

  • Avoid repeated freeze-thaw cycles (limit to 5 maximum)

• Working solution preparation:

  • Thaw aliquots completely before use

  • Mix gently by inversion or mild vortexing

  • Centrifuge briefly before opening to collect all liquid

  • Prepare fresh dilutions for each experiment

• Shipping and handling:

  • Upon receipt, immediately store at recommended temperature

  • Inspect for clarity; slight precipitates may form but should dissolve upon gentle warming

  • Maintain cold chain during transportation between laboratories

• Quality control:

  • Include positive controls in each experiment to confirm antibody performance

  • Document lot numbers and maintain records of antibody performance

  • Consider verification testing when receiving new lots

Antibody stability data indicates that SLC39A7 antibodies are typically shipped with polar packs and should be stored immediately at 4°C upon receipt for short-term use or aliquoted and stored at -20°C for long-term preservation . The presence of 0.02% sodium azide as a preservative helps maintain antibody stability during storage .

How can I quantitatively analyze SLC39A7 expression data from Western blots or immunohistochemistry?

For rigorous quantitative analysis of SLC39A7 expression, implement these methodological approaches:

• Western blot quantification:

  • Include loading controls (β-actin, GAPDH) for normalization

  • Use serial dilutions of samples to establish a linear detection range

  • Apply densitometry software (ImageJ, Image Lab) for band intensity measurement

  • Express results as relative SLC39A7/loading control ratios

  • Include at least 3 biological replicates for statistical validity

• Immunohistochemistry/Immunofluorescence quantification:

  • Capture multiple representative images per sample (minimum 5-10 fields)

  • Maintain identical acquisition parameters across all samples

  • Measure parameters such as:

    • Staining intensity (mean fluorescence intensity)

    • Percent positive cells

    • Subcellular distribution patterns

  • Use automated analysis software to reduce subjective bias

• Statistical considerations:

  • Apply appropriate statistical tests based on data distribution

  • Include multiple technical and biological replicates

  • Calculate coefficient of variation to assess reproducibility

  • Present data with appropriate error bars (SEM or SD)

• Normalization strategies:

  • For Western blots: normalize to housekeeping proteins

  • For immunofluorescence: use DAPI or other nuclear stains for cell counting

  • Consider sample-to-sample variations in background signal

When analyzing SLC39A7 expression in response to stimuli such as BCG infection, both mRNA and protein levels should be measured, as research has shown significant increases in both following infection . Independent antibody validation approaches can strengthen confidence in quantitative results by confirming consistent expression patterns across multiple detection methods .

What are emerging research areas involving SLC39A7 that could benefit from antibody-based techniques?

Several cutting-edge research areas involving SLC39A7 could benefit significantly from antibody-based techniques:

• Single-cell analysis of SLC39A7 expression:

  • Apply multiplexed immunofluorescence to identify cell-type specific expression patterns

  • Combine with zinc sensors to correlate SLC39A7 expression with functional zinc transport

  • Integrate with single-cell transcriptomics for comprehensive expression profiling

• SLC39A7 in immune cell differentiation and function:

  • Investigate SLC39A7's role in different immune cell lineages beyond macrophages

  • Study temporal expression changes during cell differentiation processes

  • Examine how SLC39A7 expression correlates with functional immune responses

• Post-translational modifications of SLC39A7:

  • Develop modification-specific antibodies (phospho-SLC39A7, ubiquitinated-SLC39A7)

  • Investigate how these modifications regulate transport activity

  • Study enzymes responsible for these modifications as potential therapeutic targets

• SLC39A7 interactome mapping:

  • Use antibodies for co-immunoprecipitation followed by mass spectrometry

  • Identify protein-protein interactions that regulate SLC39A7 function

  • Develop proximity labeling approaches to map spatial relationships

Research has already established SLC39A7's importance in macrophage function, particularly in phagocytosis and polarization . Future studies could expand on its role in other immune cell types and explore its potential as a therapeutic target in inflammatory and immune-mediated diseases.

How can SLC39A7 antibodies be used to investigate zinc homeostasis mechanisms in different cellular compartments?

SLC39A7 antibodies can be powerful tools for investigating zinc homeostasis across cellular compartments:

• Subcellular localization studies:

  • Perform co-localization analysis with organelle markers

  • Use super-resolution microscopy for precise spatial distribution

  • Compare distribution patterns under normal vs. zinc-deficient conditions

• Zinc flux monitoring:

  • Combine SLC39A7 immunostaining with zinc-specific fluorescent probes

  • Track temporal changes in zinc distribution following stimulation

  • Correlate SLC39A7 localization with local zinc concentrations

• Organelle isolation and analysis:

  • Isolate subcellular fractions (endoplasmic reticulum, Golgi, endosomes)

  • Use Western blotting to quantify SLC39A7 in each fraction

  • Compare zinc content of organelles with SLC39A7 expression levels

• Live-cell imaging approaches:

  • Develop non-interfering antibody-based probes for live-cell applications

  • Monitor real-time changes in SLC39A7 distribution during cellular processes

  • Correlate with functional readouts of cellular activation

Research has demonstrated that SLC39A7 deficiency creates a zinc-deficient cellular state, affecting multiple aspects of macrophage function . These defects can be reversed with zinc supplementation, suggesting that SLC39A7 plays a critical role in maintaining appropriate zinc distribution across cellular compartments .

What methodological innovations could enhance the utility of SLC39A7 antibodies in research?

Several methodological innovations could significantly advance SLC39A7 research using antibodies:

• Nanobody development:

  • Generate single-domain antibodies (nanobodies) against SLC39A7

  • Improve penetration into tissue sections and access to conformational epitopes

  • Enable super-resolution microscopy approaches with lower linkage error

• Proximity labeling technologies:

  • Couple SLC39A7 antibodies with enzyme tags (HRP, APEX2, TurboID)

  • Map the local proteome around SLC39A7 in different cellular contexts

  • Identify transient interaction partners under various stimulation conditions

• Multiplexed detection systems:

  • Develop antibody panels for simultaneous detection of multiple zinc transporters

  • Implement cyclic immunofluorescence or mass cytometry approaches

  • Create comprehensive zinc homeostasis profiles across cell types

• Structure-function analysis:

  • Generate conformation-specific antibodies that distinguish active vs. inactive states

  • Develop antibodies that recognize specific functional domains

  • Use these tools to understand structure-function relationships of SLC39A7

• Therapeutic applications:

  • Explore antibody-based approaches to modulate SLC39A7 function

  • Develop antibody-drug conjugates targeting cells with aberrant SLC39A7 expression

  • Investigate potential diagnostic applications in diseases with altered zinc homeostasis

Current research already utilizes multiple complementary techniques to study SLC39A7, including CRISPR-Cas9 gene editing, Western blotting, quantitative PCR, and functional assays . Future methodological innovations could build upon this foundation to provide even more detailed insights into SLC39A7 biology.